Compare · AKUS vs ASH
AKUS vs ASH
Side-by-side comparison of Akouos Inc. (AKUS) and Ashland Inc. (ASH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKUS and ASH operate in Specialty Chemicals (Consumer Discretionary), so they compete in similar markets.
- ASH carries a market cap of $3.46B.
- ASH has hit the wire 6 times in the past 4 weeks while AKUS has been quiet.
- ASH has more recent analyst coverage (25 ratings vs 1 for AKUS).
- Company
- Akouos Inc.
- Ashland Inc.
- Price
- -
- -
- Market cap
- -
- $3.46B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Specialty Chemicals
- Specialty Chemicals
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 6
- Recent ratings
- 1
- 25
Akouos Inc.
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. Akouos, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.
Ashland Inc.
Ashland Global Holdings Inc. provides specialty chemical solutions worldwide. The company's Specialty Ingredients segment offers products, technologies, and resources for solving formulation and product-performance challenges. It provides solutions using natural, synthetic, and semisynthetic polymers derived from cellulose ethers, vinyl pyrrolidones, acrylic polymers, polyester and polyurethane-based adhesives, and plant and seed extracts. This segment offers its solutions for the pharmaceutical companies; makers of personal care products, food, and beverages; makers of nutraceuticals and supplements; manufacturers of paint, coatings, and construction materials; packaging and converting markets; and oilfield service companies. Its Intermediates and Solvents produces 1,4 butanediol and related derivatives, including n-methylpyrrolidone that are used as chemical intermediates in the production of engineering polymers and polyurethanes, as well as specialty process solvents used in electronics, pharmaceuticals, water filtration membranes, and others. The company was formerly known as Ashland Inc. and changed its name to Ashland Global Holdings Inc. in September 2016. Ashland Global Holdings Inc. was founded in 1924 and is based in Wilmington, Delaware.
Latest AKUS
- SEC Form SC 13G/A filed by Akouos Inc. (Amendment)
- SEC Form SC 13G/A filed by Akouos Inc. (Amendment)
- SEC Form SC 13G/A filed by Akouos Inc. (Amendment)
- SEC Form SC 13G/A filed by Akouos Inc. (Amendment)
- SEC Form 15-12G filed by Akouos Inc.
- SEC Form EFFECT filed by Akouos Inc.
- SEC Form 4 filed by Walker Paul Edward (tax withholding)
- SEC Form 4 filed by Sonsini Peter W. (tax withholding)
- SEC Form 4 filed by Sandell Scott D to satisfy withholding tax
- SEC Form 4 filed by Mathers Edward T (tax withholding)
Latest ASH
- Amendment: SEC Form SCHEDULE 13G/A filed by Ashland Inc.
- Ashland board authorizes quarterly dividend
- Ashland Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Ashland reports fourth quarter and full-year fiscal 2026 results and issues outlook for fiscal 2027
- Amendment: SEC Form SCHEDULE 13G/A filed by Ashland Inc.
- Ashland sets date for fourth-quarter fiscal 2026 earnings release and conference call webcast
- ConnectM Forms Strategic Advisory Board to Drive AI Energy Infrastructure Growth; Appoints Ashland Director Ashish Kulkarni, Former Fortress and Shumway Capital Executive Neil Bhatia, and Las Olas Capital CEO Jim McCabe
- SEC Form 4 filed by Director Bishop Steven D
- SEC Form 4 filed by Director Chattopadhyay Sanat
- SEC Form 8-K filed by Ashland Inc.